



**Pharmaceutical
Division**

Miles Inc.
400 Morgan Lane
West Haven, CT 06516
203 937-2000

December 14, 1987

Robert R. Green, M.D.
45 South Main Street
Heber City, UT 84032

Dear Dr. Green:

Miles is pleased to introduce Cipro® Tablets (ciprofloxacin HCl/Miles), a revolutionary oral antimicrobial with parenteral-like potency. Totally synthetic, Cipro® is structurally unrelated to penicillins, cephalosporins, or tetracyclines.

Cipro® is the most potent of a new quinolone class of oral antimicrobial agents¹⁻³--and the only quinolone indicated for infections beyond the urinary tract.* In clinical trials, Cipro® achieved a favorable response in over 94% of infection sites, including infections of the lower respiratory tract, urinary tract, skin/skin structure, and bones and joints; and in infectious diarrhea.⁴

Cipro® is the most potent oral agent against methicillin-resistant Staphylococcus aureus¹ and "...the most potent anti-pseudomonas agent yet...."^{5*} Cipro® also has high in vitro activity against most of the Enterobacteriaceae, including Escherichia coli, Proteus, Klebsiella, and Enterobacter species, and Serratia marcescens; Campylobacter species; Haemophilus influenzae; Legionella species; coagulase-negative Staphylococcus species; and Streptococcus pneumoniae, Streptococcus pyogenes, and Enterococcus species.* The enclosed Prescribing Information contains a complete list of the organisms indicated for each infection.

Low minimal inhibitory concentrations (MICs),^{6*} rapid bactericidal action,⁷ and high tissue and fluid levels^{8-11**} achieved with Cipro® Tablets allow for oral treatment of many infections that previously were treatable only with injectable antibiotics.

Cipro® Tablets provide parenteral-like potency without the discomfort, inconvenience, and potential complications of injectable antibiotics. Cipro® is well tolerated. In clinical trials, the most commonly observed adverse reactions, drug related or not, have been nausea (5.2%), diarrhea (2.3%), vomiting (2.0%), abdominal pain/discomfort (1.7%), headache (1.2%), rash (1.1%), and restlessness (1.1%). Other adverse reactions were each reported in fewer than 1% of patients.⁴



Ran Tucker

Wasatch

Wawe

Wm. Bethers - 1173
372

Bowers

P 866

ace Bethers

Canon Daniels

B7H Museum

Lee Kames

Joseph Smith in
Hilderness
Rhodes

Bro Brigham
Cold
Jorgensen

ADD
RIDAURA.
BRAND OF
auranofin

for
BENEFIT BEYOND THE NSAIDs
in Rheumatoid Arthritis

See back for complete prescribing information.

ADD
RIDAURA.
BRAND OF
auranofin

for
BENEFIT BEYOND THE NSAIDs
in Rheumatoid Arthritis

See back for complete prescribing information.